Haemonetics FY27 Q1 adjusted EPS rises 3.6% to $1.14; revenue climbs 5.6% to $339.4 million
HAE•Quarterly results
Haemonetics posted Q1 fiscal 2027 revenue of $339.4 million, up 5.6% from a year earlier.
GAAP net income slipped to $33 million while GAAP diluted EPS rose to $0.72.
Adjusted diluted EPS increased 3.6% to $1.14; GAAP operating income climbed 6.7% to $57.5 million.
Cash flow and outlook
Operating cash flow rose to $52.3 million; free cash flow increased to $39.1 million.
Haemonetics raised its fiscal 2027 reported revenue growth outlook to 5%-8% from 4%-7%; organic revenue growth is seen at 4%-7% from 3%-6%.
